9A1H | pdb_00009a1h

Integrative structural model of alpha-synuclein compact states bound to membrane mimics

Integrative structure models are generated using different types of input information, including varied experimental data, physical principles, statistical preferences, and other prior information.


Integrative Structure Snapshot

  • Multi-Scale: No 
  • Multi-State: No 
  • Ordered-State: No 
  • Deposited Models: 
  • Representative Model: 

This is version 1.0 of the entry. See complete history

Literature

High-resolution structural information of membrane-bound alpha-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599

Schwarz, Thomas C.Beier, AndreasLedolter, KarinGossenreiter, ThomasHofurthner, TheresaHartl, MarkusBaker, Terry S.Taylor, Richard J.Konrat, Robert

(2023) Proc Natl Acad Sci U S A 120: e2201910120-e2201910120

  • DOI: https://doi.org/10.1073/pnas.2201910120
  • Primary Citation Related Structures: 
    9A1H

  • PubMed Abstract: 

    α-synuclein (αS) is an intrinsically disordered protein whose functional ambivalence and protein structural plasticity are iconic. Coordinated protein recruitment ensures proper vesicle dynamics at the synaptic cleft, while deregulated oligomerization on cellular membranes contributes to cell damage and Parkinson's disease (PD). Despite the protein's pathophysiological relevance, structural knowledge is limited. Here, we employ NMR spectroscopy and chemical cross-link mass spectrometry on 14 N/ 15 N-labeled αS mixtures to provide for the first time high-resolution structural information of the membrane-bound oligomeric state of αS and demonstrate that in this state, αS samples a surprisingly small conformational space. Interestingly, the study locates familial Parkinson's disease mutants at the interface between individual αS monomers and reveals different oligomerization processes depending on whether oligomerization occurs on the same membrane surface (cis) or between αS initially attached to different membrane particles (trans). The explanatory power of the obtained high-resolution structural model is used to help determine the mode-of-actionof UCB0599. Here, it is shown that the ligand changes the ensemble of membrane-bound structures, which helps to explain the success this compound, currently being tested in Parkinson's disease patients in a phase 2 trial, has had in animal models of PD.


  • Organizational Affiliation
    • Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Vienna 1030, Austria.

Macromolecule Content 

  • Total Structure Weight: 26.1 kDa 
  • Atom Count: 1,636 
  • Modeled Residue Count: 220 
  • Deposited Residue Count: 220 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:
|   3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
alpha-synuclein
A, B
110Homo sapiensMutation(s): 0 
Gene Names: SNCA
UniProt & NIH Common Fund Data Resources
Find proteins for P37840 (Homo sapiens)
Explore P37840 
Go to UniProtKB:  P37840
PHAROS:  P37840
GTEx:  ENSG00000145335 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP37840
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Integrative Structure Snapshot

  • Multi-Scale: No 
  • Multi-State: No 
  • Ordered-State: No 
  • Deposited Models: 
  • Representative Model: 

Structure Validation

View Full Validation Report

View Summary Validation Report



Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2023-04-28
    Type: Initial release